List of Excipients in Branded Drug LATISSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	LATISSE	bimatoprost	0023-3616	BENZALKONIUM CHLORIDE
Allergan Inc	LATISSE	bimatoprost	0023-3616	CITRIC ACID MONOHYDRATE
Allergan Inc	LATISSE	bimatoprost	0023-3616	SODIUM CHLORIDE
Allergan Inc	LATISSE	bimatoprost	0023-3616	SODIUM PHOSPHATE, DIBASIC
Allergan Inc	LATISSE	bimatoprost	0023-3616	WATER

LATISSE Excipient Strategy and Commercial Opportunities in Bimatoprost Eyelash Treatment

Last updated: October 4, 2026

LATISSE is Allergan’s prescription bimatoprost ophthalmic solution, 0.03%, approved by the U.S. Food and Drug Administration in December 2008 for increasing the length, fullness, and darkness of eyelashes in patients with hypotrichosis [1]. Its commercial formulation is a sterile, preserved aqueous solution containing bimatoprost, benzalkonium chloride, sodium chloride, phosphate buffer, citric acid, purified water, and pH-adjusting agents [2].

The main commercial opportunity is not a new active ingredient. It is differentiated delivery: preservative-free or low-irritation formulations, single-use applicators, controlled dosing, improved stability, and products positioned for dermatologist, ophthalmologist, and consumer-aesthetic channels.

What excipients are used in LATISSE?

LATISSE uses a conventional ophthalmic excipient system designed to maintain sterility, pH, tonicity, and chemical stability.

Component	Function in LATISSE
Bimatoprost, 0.03%	Active pharmaceutical ingredient
Benzalkonium chloride, 0.05 mg/mL	Preservative
Sodium chloride, 8.0 mg/mL	Tonicity adjustment
Sodium phosphate dibasic, 1.38 mg/mL	Buffering agent
Citric acid, 0.14 mg/mL	Buffer and pH control
Hydrochloric acid and/or sodium hydroxide	pH adjustment
Purified water	Vehicle

The labeled pH is approximately 7.4. The formulation is supplied in a multidose bottle and used once daily on the upper eyelid margin with a sterile applicator [2].

Benzalkonium chloride is the most commercially relevant excipient in the formulation. It supports multidose sterility but is associated with ocular-surface irritation and epithelial toxicity concerns, particularly with chronic ophthalmic exposure. LATISSE is applied to the eyelid margin rather than instilled directly into the eye, but ocular contact can occur. This creates a formulation-development opening for preservative-free and low-preservative alternatives.

How does the LATISSE formulation support product performance?

Bimatoprost is a prostamide analogue with limited aqueous solubility. At the low concentration used in LATISSE, the commercial product avoids a complex solubilization platform. The formulation instead relies on a simple buffered aqueous vehicle and a low active concentration.

The principal formulation requirements are:

1. Maintaining bimatoprost assay and degradation profile throughout shelf life.
2. Preserving sterility after repeated container opening.
3. Limiting precipitation or adsorption to the container and applicator.
4. Maintaining acceptable pH and osmolality at the eyelid margin.
5. Preventing microbial contamination during daily use.
6. Delivering a reproducible small dose without excess runoff into the eye.

The simplicity of the excipient system reduces manufacturing complexity. It also leaves room for competitive products that use a more advanced container-closure or dosing system without materially changing the active ingredient.

What excipient strategies could improve LATISSE?

Preservative-free multidose delivery

The strongest formulation opportunity is a preservative-free multidose package. Potential technologies include:

• One-way valve containers.
• Airless multidose pumps.
• Sterile metered-dose dispensers.
• Unit-dose ampoules.
• Sterile, individually packaged eyelid applicators.
• Container systems with microbial ingress barriers.

A preservative-free version could target patients who experience redness, itching, periocular irritation, or ocular-surface sensitivity. It could also support premium positioning in dermatology and medical aesthetics.

The commercial tradeoff is cost. A conventional bottle with benzalkonium chloride is inexpensive and familiar. Preservative-free packaging requires more complex device validation, extractables and leachables testing, microbial integrity studies, and manufacturing controls.

Reduced-irritation preservative systems

A second option is replacing benzalkonium chloride with a less irritating preservative or preservative combination. Candidate systems used elsewhere in ophthalmic products include polyquaternium-1, stabilized oxychloro complexes, borate-based systems, and oxidative preservative technologies.

The active ingredient and indication would remain unchanged, but the formulation could support a new drug application supplement or a separate 505(b)(2) strategy, depending on the scope of formulation and clinical bridging. The regulatory burden would include preservative efficacy, ocular tolerability, stability, and comparative performance data.

Improved applicator compatibility

LATISSE’s product performance depends on the applicator as much as the bottle. A redesigned applicator could:

• Reduce retained product volume.
• Limit contact between the applicator and eyelashes or skin.
• Improve dose consistency.
• Reduce cross-contamination.
• Prevent reuse.
• Deliver the solution only to the upper eyelid margin.

A single-use applicator is commercially attractive because it addresses contamination and dosing concerns. It increases packaging expense and waste, but the cost may be acceptable for a premium eyelash-growth product.

Viscosity and residence-time modification

A modest increase in viscosity could improve retention at the eyelid margin and reduce runoff. Potential excipients include low concentrations of hydroxypropyl methylcellulose, hydroxyethylcellulose, carbomers, or other ophthalmically acceptable polymers.

This strategy has technical limits. Excessive viscosity can cause stringiness, applicator loading problems, blurred vision if the product reaches the eye, and inconsistent dose delivery. A viscosity-modified formulation would require comparative tolerability and human-use testing.

Solubilization and stabilization

A redesigned formulation could use surfactants, cyclodextrins, lipid-based vehicles, or other solubilizers to improve chemical stability or enable a lower-volume dose. These systems may also increase irritation risk or complicate manufacturing.

The most defensible development strategy is a targeted formulation change rather than a broad excipient overhaul. The commercial objective is to solve one problem, such as irritation or dosing precision, while preserving the established bimatoprost concentration and route of administration.

What patents protect LATISSE and its formulation?

The core intellectual-property position historically centered on bimatoprost use for eyelash hypotrichosis rather than on a complex excipient platform.

IP category	Relevance to LATISSE
Bimatoprost composition patents	Protect the active ingredient and certain pharmaceutical compositions
Method-of-use patents	Cover treatment of eyelash hypotrichosis and related hair-growth indications
Formulation patents	May cover concentration, pH, preservatives, stability, or delivery systems
Device patents	May cover applicators, containers, dosing systems, or sterile packaging
Trademark rights	Protect the LATISSE brand and commercial identity

U.S. Patent No. 7,351,404, assigned to Allergan, covered methods involving bimatoprost for treating hypotrichosis and was issued in 2008 [3]. The patent’s effective expiration depended on its patent-term calculation and any applicable adjustment. Patent-term analysis must be performed against the official USPTO record and Orange Book listings rather than inferred from the issue date.

The commercial protection for LATISSE has therefore depended on a combination of indication-specific rights, regulatory exclusivity, brand recognition, and manufacturing know-how. A new excipient system can create additional protection if the claims cover a specific composition, preservative-free configuration, stability profile, container, applicator, or method of use.

What is the FDA and Orange Book status of LATISSE?

LATISSE was approved under NDA 022369 for acquired eyelash hypotrichosis [1]. The product is a prescription drug, although its commercial use overlaps with cosmetic and aesthetic services.

The regulatory distinction is important:

• LATISSE is approved for eyelash hypotrichosis.
• Cosmetic eyelash-growth products may not contain bimatoprost unless authorized under applicable drug regulations.
• A product marketed with claims to grow eyelashes can be treated as a drug based on its intended use.
• A generic bimatoprost ophthalmic product approved for glaucoma does not automatically have approval for eyelash hypotrichosis.
• An abbreviated new drug application may rely on the reference product for certain pharmaceutical-equivalence elements, but indication, labeling, patent certification, and exclusivity issues remain material.

Orange Book listings should be reviewed for current patent status, expiration dates, and any changes to the reference-listed drug record [4]. A formulation developer should not assume that ophthalmic bimatoprost approval eliminates method-of-use or labeling-related barriers.

When does LATISSE lose exclusivity?

LATISSE’s exclusivity has several separate components.

Regulatory exclusivity

The original approval date was December 2008. New-drug exclusivity associated with the original approval would have expired years ago. Any remaining commercial protection would therefore depend primarily on patents, regulatory labeling, product differentiation, and brand equity rather than original new-drug exclusivity.

Patent exclusivity

The key patent question is whether a current patent remains listed or enforceable against a proposed product and whether the proposed product’s label induces use for eyelash hypotrichosis. Historical method-of-use patents have been central to the LATISSE estate.

Trademark exclusivity

The LATISSE trademark can continue after drug patents expire, subject to maintenance and use requirements. A generic or competing bimatoprost product cannot use the LATISSE name or create a confusingly similar presentation.

Which companies are challenging LATISSE, and what generic entry risks exist?

Competition can arise from three product categories:

1. Generic bimatoprost ophthalmic solutions approved for glaucoma.
2. New drug products seeking eyelash-hypotrichosis labeling.
3. Nonprescription cosmetic serums using peptides, prostaglandin analogues, botanical extracts, or conditioning agents.

A generic manufacturer may seek approval for a bimatoprost ophthalmic solution with a glaucoma indication while omitting the eyelash-growth indication through a section viii strategy, where permitted. The risk to LATISSE would depend on whether the generic product is prescribed or promoted for eyelash use and whether the patent claims cover the approved label or actual commercial conduct.

A direct generic launch with eyelash-hypotrichosis labeling would face greater scrutiny concerning listed patents, Paragraph IV certifications, labeling carve-outs, and infringement risk. Publicly confirmed litigation and settlement terms should be checked in the relevant federal court docket and FDA patent certifications before assigning a launch date.

What commercial opportunities exist for LATISSE excipient innovation?

Premium prescription formulation

A preservative-free or reduced-irritation LATISSE-type product could support a premium price and specialist distribution. The target population would include patients with ocular-surface sensitivity, chronic dry eye, contact-lens use, or prior intolerance to benzalkonium chloride.

Dermatology and aesthetic clinics

A clinic-dispensed formulation with controlled applicators could reduce misuse and support professional counseling. The product could be bundled with eyelid-care protocols, lash procedures, or post-procedure treatment plans.

Single-use packaging

Unit-dose packaging offers a clear hygiene proposition. It is most attractive where contamination concerns or patient adherence justify a higher cost. The principal barriers are packaging cost, filling-line changes, waste, and supply-chain volume.

Authorized generic or branded-generic strategy

A manufacturer could pursue a bimatoprost 0.03% product with a lower-cost bottle and a regulatory label limited to an approved ophthalmic indication. A differentiated excipient system could support a separate branded product, but the market would be highly price-sensitive if multiple generic suppliers enter.

Cosmetic-adjacent products

Conditioning serums without bimatoprost could target consumers seeking longer or fuller-looking lashes without prescription access. These products may use panthenol, peptides, amino acids, humectants, film-formers, and botanical ingredients. They must avoid drug-like eyelash-growth claims unless supported by an approved drug pathway.

How strong is the LATISSE patent estate?

The estate is stronger in method-of-use and brand protection than in excipient complexity. The commercial formulation uses widely known ophthalmic excipients, which limits the scope for broad composition claims. New protection would be more credible around:

• A specific preservative-free bimatoprost composition.
• A defined pH, osmolality, viscosity, and stability profile.
• A container-applicator combination.
• A sterile single-use delivery system.
• A method that reduces periocular irritation while maintaining efficacy.
• A formulation with improved delivery to the upper eyelid margin.

Freedom-to-operate analysis should cover composition claims, use claims, container-closure patents, applicator patents, and regulatory-label strategy. Manufacturing know-how may be more important than excipient patent breadth where the formulation itself is simple.

Key Takeaways

• LATISSE contains bimatoprost 0.03% in a buffered aqueous formulation with benzalkonium chloride, sodium chloride, phosphate, citric acid, purified water, and pH adjusters.
• Benzalkonium chloride is the principal excipient-driven differentiation opportunity.
• Preservative-free multidose packaging, single-use applicators, and reduced-irritation systems offer the clearest commercial paths.
• Generic glaucoma bimatoprost approval does not automatically create approval for eyelash hypotrichosis.
• The historic patent position has focused more on bimatoprost use for hypotrichosis than on a sophisticated excipient platform.
• New formulation patents are most likely to succeed when they claim a defined composition combined with a device, stability benefit, dosing feature, or tolerability result.
• Competitive risk comes from generics, new prescription products, and cosmetic eyelash serums.

FAQs About LATISSE Excipients and Commercial Strategy

Is benzalkonium chloride necessary in LATISSE?

It supports multidose preservation but is not inherently required for every bimatoprost formulation. A preservative-free package or alternative antimicrobial system could replace it if sterility, stability, safety, and regulatory requirements are met.

Can a preservative-free bimatoprost product compete directly with LATISSE?

Yes. A product could compete through a new drug application, an appropriate abbreviated pathway, or a formulation-focused regulatory strategy. The commercial advantage would be reduced-irritation positioning and improved patient tolerability.

Does the LATISSE formulation contain prostaglandin?

LATISSE contains bimatoprost, a prostamide analogue structurally related to prostaglandin compounds. It is not labeled as a conventional prostaglandin ophthalmic drug.

Are cosmetic eyelash serums generic alternatives to LATISSE?

No. Cosmetic serums generally do not have the same active ingredient, clinical evidence, FDA indication, or regulatory status. Products marketed to grow eyelashes may fall within drug regulation based on their claims.

What is the highest-value excipient innovation for bimatoprost eyelash products?

The highest-value opportunity is a low-irritation, preservative-free delivery system that provides reproducible eyelid-margin dosing while maintaining sterility and chemical stability.

References

1. U.S. Food and Drug Administration. (2008). Latisse (bimatoprost ophthalmic solution) 0.03% approval letter and prescribing information. FDA.

2. DailyMed. (n.d.). LATISSE- bimatoprost ophthalmic solution, 0.03% prescribing information. National Library of Medicine.

3. U.S. Patent and Trademark Office. (2008). U.S. Patent No. 7,351,404: Treatment of hypotrichosis with bimatoprost. USPTO.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.